Background: Due to the uncommon nature of primary spinal epidural lymphomas (PSELs), there has been little research looking at prognostic indicators for the tumor. To our knowledge, this is the largest study to evaluate possible clinical and pathologic prognostic factors in PSEL patients.
Background
Primary spinal epidural lymphomas (PSELs) are very rare, and relatively few such tumors have been reported in the literature. Although PSEL accounts for 10% of all epidural spinal tumors [1] , the epidural location is a rare site of presentation for lymphomas, characterizing only 0.1 to 3.3% of all lymphomas [2, 3] . Due to the rarity of the condition, it is difficult to enroll a sufficient number of patients with PSEL to adequately evaluate possible factors associated with survival. The largest series to date, reported by Monnard et al. [4] , identified 52 patients over 20 years . However, the limited number of patients and the long time span have made it difficult to establish the disease parameters, such as the natural history of the disease, prognostic indicators, treatment techniques employed, and survival rates. For this study, we identified only retrospective studies, which included reports on relatively small numbers of patients or single case reports. The goal of this study was to help identify the clinical profile, treatment outcomes, and significant prognostic indicators in PSEL patients.
Methods

Patient characteristics
A total of 130 PSEL cases were retrospectively reviewed, including 36 Chinese patients and 94 published case reports from 1985 to 2015. Patients were selected if there was a conclusive histopathologic diagnosis of PSEL with complete clinical pathology, and there was no history of previous malignant disease or a second primary tumor. The 130 patients included 76 men (58%), 44 women (34%) and 10 unknown (8%), for a known male-to-female ratio of 1.73. The median age was 45 years (range, 3-80 years), and median follow-up was 32 months (range, 1-149 months). Clinical and pathological variables analyzed included patient age and gender; tumor stage, differentiation, location, and range; and treatment modalities employed (Table 1) .
Treatment
Most patients diagnosed with stage IE-IIE PSEL had been treated with tumorectomy (n = 121, 93%); the rest had surgical contraindications or refused surgery. The primary treatment of patients consisted primarily of surgery. Individualized postoperative treatment consisted of radiation therapy alone (n = 26, 21%), chemotherapy alone (n = 20, 25%), or concurrent chemoradiation therapy (n = 41, 49%). The median radiotherapy dose was 40 Gy (range, 20-50 Gy), and the total dose was administered over 3-5 weeks. Twenty-eight patients (34%) had only focal treatment, whereas the remaining 55 (66%) received more than focal treatment. Eight-two patients (63%) had chemotherapy, which consisted of cyclophosphamide, doxorubicin, vincristine, and prednisone in the majority of patients; methotrexate, leucovorin, etoposide, and bleomycin were also used in some patients. Generally, 4-8 cycles of chemotherapy were administered at 3-week intervals. Methotrexate was administered in 21 patients (26%).
Statistical analysis
The Kaplan-Meier method and log-rank tests were used to determine overall survival (OS) and disease-free survival (DFS). Independent prognostic factors for OS and DFS were identified using the Cox proportional hazards model. SPSS software (version 13.0, SPSS Inc., Chicago, IL) was used for all statistical analyses, and P values < 0.05 were considered statistically significant.
Results
Clinical features
The median patient age was 45 years (range, 3-80 years). In three of the 130 patients (2%), PSEL was detected during a routine examination. Alternatively, 112 of the patients (86%) presented with neck, back, lumbosacral, or limb pain, or with cord compression syndrome. For 15 cases (12%) reviewed from published case reports, the details of presentation were not provided. The most commonly reported symptoms were motor weakness or hypoesthesia (62%), back pain (59%), lumbosacral pain (32%), limb pain (28%), neck pain (9%), bowel dysfunction (23%), bladder dysfunction (19%), and low-grade fevers (2%). The time from the first symptom to diagnosis varied from 3 days to 5 years. Patient characteristics are presented in Additional file 1: Table S1 and Additional file 2: Table S2 .
Pathologic features
Case reviews showed tumor pathologies of B-cell lymphoma (n = 88, 76%), T-cell lymphoma (n = 13, 11%), or Burkitt's lymphoma (n = 15, 13%). Subsets of cases were Table S1 and Additional file 2: Table S2 .
Survival
The median follow-up period was 32 months. Relapses were observed in 21 patients (19%) after a median period of 12 months, primarily in the central nervous system (n = 11), lymph nodes (n = 4), chest or abdomen (n = 5), and liver (n = 2). The 3-year OS and DFS were 81.1 and 46.3%, respectively.
Prognostic factors
In order to identify potential prognostic factors associated with survival in PSEL patients, various clinicopathologic variables were evaluated ( Table 2) . Using univariate analysis, gender, pathological pattern, tumor differentiation, tumor location, and tumor range were found to be associated with OS (P < 0.05), but not with DFS. The 3-year OS rates for males and females were 60.3% and 100% (P = 0.002), respectively (Fig. 1a) . The 3-year OS rates for thoracic, cervical, and lumbosacral spine locations were 64.1, 94.3, and 100% (P = 0.005), respectively (Fig. 1b) . The 3-year OS rates for B-cell, T-cell, and Burkitt's lymphoma were 87.7, 83.3, and 29.5% (P = 0.002), respectively (Fig. 1c) . In terms of treatments received, the 3-year DFS rate for patients receiving S alone was 23.3% (P = 0.004, compared with the other treatment groups; Fig. 2 ), while patients receiving S + RT + CT had a 3-year DFS rate of 49.6% (P = 0.031, compared with the other treatment groups, Fig. 3) ; patients receiving S + CT had a 3-year DFS rate of 50.4% (P = 0.042, compared with the other treatment groups; Fig. 4 
Discussion
With a study cohort of 130 patients treated over a 30-year period, the current study represents the largest one to focus on PSEL. Prior to this, the largest one reported on only 52 patients, and predated modern radiotherapy and chemotherapy protocols. The origin of primary spinal epidural lymphomas (PSEL) remains controversial. It is known that lymphoma may arise anywhere lymphatic tissue is found. However, whether there is lymphoid tissue in the epidural space has been debated [5, 6] . Rubinstein was the first to [7] . Some have suggested that PSEL may originate from either paraspinal, spinal, or retroperitoneal tissues, accessing the epidural space via the interspinal foramina [8, 9] . However, the occurrence of lymphoma in this location indicates that lymphoid precursor cells are present in the space. Metastasis is the most common sacral malignancy, whereas chordoma in the most common primary sacral tumor [10] . PSELs represent 10% of epidural spinal tumors, but the epidural location is a rare presenting site for lymphomas, being seen in only 0.1 to 3.3% of all lymphomas. When lymphoma has been found in the spine, it has been reported most often in the lumbar or lower dorsal area [11] . However, in this study, we found the thoracic spine to be the most common site (62%) for lymphoma. The most common presenting symptoms reported in the literature have included lower limb weakness, localized back pain, and bladder dysfunction [8, 9] . However, in this study, the most common symptoms seen were motor weakness or hypoesthesia (62%), back pain (59%), lumbosacral pain (32%), limb pain (28%), neck pain (9%), bowel dysfunction (23%), bladder dysfunction (19%), and low-grade fevers (2%). It is noteworthy that most patients presented with persistent back pain for considerably long periods of time prior to diagnosis. Therefore, persistent back pain in a patient should be considered a warning symptom for a more serious illness.
On histopathological examination, these tumors show atypical lymphoid cell proliferation. On immunohistochemistry, tumor cells are positive for leukocyte common antigen (LCA) and CD20, but negative for CD138, CD30, and CD3. B-cell lymphoma is the most common type at this site [12] , which is consistent with our findings. Our study found that tumor pathologies consisted of B-cell lymphoma (76%), T-cell lymphoma (11%), and Burkitt's lymphoma (13%). Furthermore, tumor cells were associated with the strong expression of leukocyte There has been no optimization of treatment strategies for PSEL patients to improve patient outcomes. Unfortunately, there is a high mortality rate within the first year of diagnosis due to early metastasis and tumor recurrences. Accordingly, the importance of aggressive, systemic therapy has been recognized over the last few decades, although there have been reports of patients being cured with local radiotherapy alone [13] . In cases of patients who present with signs of spinal cord compression, surgical intervention for tissue diagnosis and decompression is required. Aabo et al. [14] reported no difference between the outcomes in patients who underwent decompressive laminectomy and radiotherapy and those who received spinal radiation only. Chemoradiotherapy remains the mainstay of treatment because lymphomas are highly radio-and chemosensitive tumors.
The CHOP regime, in particular, is still considered the gold standard for treatment. A radiotherapy dose of 3500 cGy to 4000 cGy delivered in 20-25 fractions over 3-4 weeks is required to achieve radical cure [9] . Intensive chemotherapy should also be initiated immediately following diagnosis and be delivered over a short period of time.
From reviewing several studies, we found that combined modality treatment is associated with a lower recurrence rate and improved disease-free survival in PSEL, but not overall survival. Similar findings have not been reported by other researchers. In this study, the median survival time of 36 Chinese patients is 12 month. It shorter than non-Chinese cases (12 VS. 27 ). Optimization of treatment strategies for Chinese patients included surgery (33/35, 94.3%), surgery followed by chemotherapy (17/35, 56.7%), surgery only (15/35, 42.9%), and surgery followed by chemotherapy and radiotherapy (5/35, 14.3%). There are less Chinese patients with PSEL treated with combined modality treatment compared to non-Chinese cases because of medical expenses. Kaplan-Meier Fig. 4 Kaplan-Meier survival curves analyze for DFS rates associated with surgery followed by chemotherapy vs. others 6 Kaplan-Meier survival curves analyze for OS rates associated with surgery followed by chemotherapy and radiotherapy vs. others Fig. 7 Kaplan-Meier survival curves analyze for OS rates associated with surgery followed by chemotherapy vs. others
